ImmunoGen, Inc.
Jul 21, 2016
PDF

ImmunoGen, Inc. Announces Conference Call to Discuss Its Fourth Quarter and Fiscal Year 2016 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, August 4, 2016, to discuss ImmunoGen's financial results for the three-month period and fiscal year ended June 30, 2016. Management also will provide an update on mirvetuximab soravtansine and other ImmunoGen product programs.

To access the live call by phone, dial 913-312-1463; the conference ID is 3243361. The call also may be accessed through the Investors section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through August 18, 2016.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate ("ADC") technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is being advanced to registration-enabling testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase¬†1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.

Kadcyla® is a registered trademark of¬†Genentech, a member of the Roche Group.

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com

Source: ImmunoGen, Inc.

News Provided by Acquire Media